

The Keyrus Group sells its Life Sciences CRO activities to the Astek Group

Levallois-Perret (France) - June 23, 2025: The **Keyrus** Group announces that it has sold its entire Life Sciences CRO activities (IFRS 2024 consolidated revenue: €23.5m - 190 FTEs) to the **Astek** Group.

Keyrus, an international "Global Player" expert in Data, Artificial Intelligence and Digital, has been developing a strong value proposition in clinical research for over 25 years, in France, Belgium, Canada and the United States, covering all phases of R&D, market access and post-marketing follow-up for pharmaceutical products.

Founded in France in 1988, **Astek** is a global player in engineering and technology consulting, with a presence on every continent. **Astek** supports its international customers in the intelligent deployment of their products and services, and in the implementation of their digital transformation. The **Astek** Group generated consolidated revenue of €720m in 2024, 11% of which in the Life Sciences sector.

The evolution of the CRO market, its technologies and the strategies of pharmaceutical companies mean that we need to reach a critical international scale, and to have substantial offshore capacities to ensure long-term relationships with Big Pharma. With this in mind, **Keyrus** has decided to back its Life Sciences CRO activities with a recognized industrial player, which will enable it to continue developing in line with the market consolidation.

"Through this operation, our group is refocusing its efforts and investments on its core Data & AI business, which requires organic resources in terms of innovation and development of new technological partnerships, and intends to participate in the consolidation of the market through external growth", declares **Eric Cohen**, Founder and Chairman of the **Keyrus** Group.

*"We chose the **Astek** Group to offer our teams the best future, both in terms of industrial vision and in terms of culture and values very similar to those of the **Keyrus** Group. **Keyrus'** Life Sciences CRO activities will henceforth be called **Alsinova**, and will continue to develop within the **Astek** Group. The know-how and quality of service we have developed over more than 25 years will be major assets for **Astek's** future projects",* adds **Marc Stukkens**, CEO of the **Keyrus** Group.

Julien Gavaldon, Chairman of the Management Board of Groupe **Astek**, comments: *"The planned acquisition of **Keyrus'** Life Sciences CRO activities illustrates our commitment to becoming a key player in the digital transformation of Life Sciences. By combining our engineering and data science skills with the expertise of **Keyrus'** CRO activities, we are ideally positioned to support our customers in their clinical, regulatory and technological challenges on a global scale".*

ABOUT KEYRUS

By combining **industry, functional** and **technological expertise** in all the most current areas of data and artificial intelligence, Keyrus helps its customers to implement the resources they need to increase their **competitiveness, resilience** and **adaptability**.

Keyrus offers a complete value proposition, covering consulting and solutions, so that the opportunities created by data, artificial intelligence (AI) and digital become a reality:

- **Data advisory & consulting**
- **Data & analytics solutions**
- **Artificial Intelligence (AI)**
- **Enterprise Performance Management (EPM)**
- **Digital & multi-experience**

Relying on the accumulated experience of more than 3200 people and present in more than 28 countries on 4 continents, **Keyrus** is one of the foremost international experts in data, consulting, and technology. Learn more at: <http://www.keyrus.com>

CONTACTS

KEYRUS

Karim.mulard-benjelloun@keyrus.com
contact-keyrus@keyrus.com